Dysautonomia Foundation was founded by parents of children with FD, shortly after the disorder was first identified in the United States.
Dysautonomia Treatment Center was established at NYU Medical Center, under the direction of Dr. Felicia Axelrod.
The Dysautonomia Center in Israel, at Hadassah Hospital-Mt. Scopus in Jerusalem, was established under the direction of Dr.Channa Maayan.
The first FD Day annual conference was held, bringing together families and caregivers for a day of learning and connecting.
Construction was completed on an expanded Dysautonomia Center at NYU, doubling the space and adding a state-of-the art Research Lab.
Dr. Horacio Kaufmann, a Professor of Neurology, joined the Center’s team as head of the new Dysautonomia Research Laboratory.
An endowed professorship was established in the NYU School of Medicine’s Department of Neurology and named in honor of Dr. Felicia B. Axelrod.
Scientists discovered the FD gene mutation IKBKAP within Chromosome 9Q, ushering in a new era of population screening and prenatal diagnosis.
The Dysautonomia Foundation began funding a second FD Center in Israel at Sheba Medical Center in Tel Hashomer. Under the direction of Dr. Ori Efrati, the Center offers a comprehensive approach to FD care.
The Dysautonomia Center expanded eye research, adding a state of the art laboratory to examine the innervation of the eye and visual function.
The Center’s Fellowship Program in Autonomic Disorders receives accreditation from the United Council of Neurological Subspecialties.
National Institutes of Health (NIH) to work with the NYU Center on both FD patients and mice to understand the cause and potential treatments for the GI problems in people with FD.
We are proud to have funded research at these institutions over our six decades of operation:
Looking Towards the Future
Our challenge is not over--FD continues to be an incurable progressive disorder and a source of daily struggle for affected patients and their families. As we move forward, the Familial Dysautonomia Foundation remains committed to improving the lives of people affected by FD and working towards a world without FD.